

Peter R Carroll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2231299/publications.pdf>

Version: 2024-02-01

222
papers

9,679
citations

57758

44
h-index

43889

91
g-index

248
all docs

248
docs citations

248
times ranked

10734
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. <i>Journal of Urology</i> , 2022, 207, 127-136.	0.4	7
2	Active surveillance in intermediate-risk prostate cancer with PSA 10–20 ng/mL: pathological outcome analysis of a population-level database. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 690-693.	3.9	8
3	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. <i>Cancer</i> , 2022, 128, 269-274.	4.1	3
4	Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. <i>European Urology Oncology</i> , 2022, 5, 537-543.	5.4	13
5	Identification of prostate cancer using multiparametric MR imaging characteristics of prostate tissues referenced to whole mount histopathology. <i>Magnetic Resonance Imaging</i> , 2022, 85, 251-261.	1.8	7
6	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100070.	1.7	10
7	Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 832-840.	0.4	8
8	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. <i>Journal of Urology</i> , 2022, 207, 805-813.	0.4	3
9	The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 1001-1009.	0.4	3
10	Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for cribriform prostatic adenocarcinoma. <i>Modern Pathology</i> , 2022, 35, 1092-1100.	5.5	10
11	Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score.. <i>Journal of Clinical Oncology</i> , 2022, 40, 35-35.	1.6	0
12	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. <i>Prostate</i> , 2022, 82, 876-879.	2.3	2
13	The effect of preoperative membranous urethral length on likelihood of postoperative urinary incontinence after robot-assisted radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 344-350.	3.9	9
14	Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis. <i>Human Pathology</i> , 2022, 122, 84-91.	2.0	6
15	Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. <i>Cancer Medicine</i> , 2022, , .	2.8	3
16	Editorial Comment. <i>Journal of Urology</i> , 2022, , 101097JU000000000000249102.	0.4	0
17	Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5024-5024.	1.6	1
18	Patient engagement in a mobile health intervention to improve preparedness for prostate biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	1.6	1

#	ARTICLE	IF	CITATIONS
19	How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound?. <i>European Urology Focus</i> , 2021, 7, 1268-1273.	3.1	6
20	Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer. <i>Prostate</i> , 2021, 81, 102-108.	2.3	6
21	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	1.9	93
22	Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy. <i>Urology</i> , 2021, 149, 168-173.	1.0	6
23	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 501-508.	6.4	30
24	Editorial Comment. <i>Journal of Urology</i> , 2021, 205, 121-121.	0.4	0
25	The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance—Does Cancer Vanish or Simply Hide?. <i>Journal of Urology</i> , 2021, 205, 109-114.	0.4	2
26	Single-cell analysis of cellular state heterogeneity in human localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 254-254.	1.6	0
27	PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.. <i>Journal of Clinical Oncology</i> , 2021, 39, 33-33.	1.6	0
28	A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance. <i>BMC Urology</i> , 2021, 21, 18.	1.4	3
29	Clinical Utility of 4Kscore [®] , ExosomeDx [®] , and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 452-460.	0.4	36
30	A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. <i>Journal of Clinical Oncology</i> , 2021, 39, 32-32.	1.6	2
31	Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. <i>Scientific Reports</i> , 2021, 11, 5040.	3.3	40
32	Editorial Comment. <i>Journal of Urology</i> , 2021, 205, 777-778.	0.4	0
33	Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 781.e17-781.e24.	1.6	10
34	Post-diagnostic coffee and tea consumption and risk of prostate cancer progression by smoking history. <i>Cancer Causes and Control</i> , 2021, 32, 635-644.	1.8	3
35	Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4367.	4.1	62
36	Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing. <i>JCO Precision Oncology</i> , 2021, 5, 710-725.	3.0	6

#	ARTICLE	IF	CITATIONS
37	SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study. <i>Cancers</i> , 2021, 13, 2047.	3.7	45
38	PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR) – A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5023-5023.	1.6	1
39	A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. <i>Journal of Clinical Oncology</i> , 2021, 39, e17003-e17003.	1.6	0
40	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , 2021, 79, 717-721.	1.9	13
41	A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4463-4471.	6.4	9
42	Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort. <i>Prostate</i> , 2021, 81, 1009-1017.	2.3	2
43	The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. Reply.. <i>Journal of Urology</i> , 2021, 206, 174-174.	0.4	1
44	Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. <i>Urology</i> , 2021, , .	1.0	1
45	Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen. <i>Journal of Urology</i> , 2021, 206, 706-714.	0.4	5
46	Association of Age With Risk of Adverse Pathological Findings in Men Undergoing Delayed Radical Prostatectomy Following Active Surveillance. <i>Urology</i> , 2021, 155, 91-95.	1.0	6
47	Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database. <i>European Urology Open Science</i> , 2021, 34, 47-54.	0.4	3
48	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 136-143.	3.9	36
49	Understanding the Major Factors Affecting Response Shift Effects on Health-Related Quality of Life: What the Then-Test Measures in a Longitudinal Prostate Cancer Registry. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e21-e27.	1.9	4
50	Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients. <i>Cancer Medicine</i> , 2020, 9, 125-132.	2.8	7
51	Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. <i>Cancer</i> , 2020, 126, 583-592.	4.1	9
52	MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort. <i>American Journal of Roentgenology</i> , 2020, 214, 574-578.	2.2	15
53	The Relative Impact of Urinary and Sexual Function vs Bother on Health Utility for Men With Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa044.	2.9	0
54	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	3.0	2

#	ARTICLE	IF	CITATIONS
55	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	7.1	49
56	Characteristics of Cancer Progression on Serial Biopsy in Men on Active Surveillance for Early-stage Prostate Cancer: Implications for Focal Therapy. <i>European Urology Oncology</i> , 2020, , .	5.4	7
57	Comparison of biopsy underâ€sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies. <i>Cancer Medicine</i> , 2020, 9, 9611-9619.	2.8	6
58	Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 793.e1-793.e11.	1.6	7
59	Re: Vasilis Stavrinos, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>Eur Urol</i> 2020;78:443â€“51. <i>European Urology</i> , 2020, 78, e110-e111.	1.9	0
60	Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 1793.	7.1	10
61	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. <i>JAMA Oncology</i> , 2020, 6, e203187.	7.1	30
62	A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer. <i>BMC Cancer</i> , 2020, 20, 820.	2.6	14
63	Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category. <i>Prostate</i> , 2020, 80, 1421-1428.	2.3	1
64	Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease. <i>Scientific Reports</i> , 2020, 10, 21750.	3.3	34
65	Impact of ⁶⁸ Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1793-1799.	5.0	74
66	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , 2020, 38, 2798-2811.	1.6	170
67	Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2020, 78, 515-517.	1.9	12
68	The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. <i>European Urology</i> , 2020, 78, 335-344.	1.9	28
69	Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4. <i>Prostate</i> , 2020, 80, 653-659.	2.3	17
70	Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. <i>Radiology</i> , 2020, 296, 76-84.	7.3	207
71	Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US. <i>JAMA Network Open</i> , 2020, 3, e2031349.	5.9	41
72	Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 1216-1221.	0.4	9

#	ARTICLE	IF	CITATIONS
73	The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 1222-1228.	0.4	30
74	Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5501-5501.	1.6	21
75	Rapid Utilization of Telehealth in a Comprehensive Cancer Center as a Response to COVID-19: Cross-Sectional Analysis. <i>Journal of Medical Internet Research</i> , 2020, 22, e19322.	4.3	127
76	18-year prostate cancer-specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 300-300.	1.6	0
77	Editorial Comment. <i>Journal of Urology</i> , 2020, 203, 1121-1121.	0.4	0
78	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 1221-1221.	0.4	0
79	Hematuria Practice Guidelines That Explicitly Consider Harms and Costs. <i>JAMA Internal Medicine</i> , 2019, 179, 1362.	5.1	3
80	Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry. <i>European Urology</i> , 2019, 76, 743-751.	1.9	5
81	Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 685-690.	5.4	21
82	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. <i>European Urology</i> , 2019, 76, 693-702.	1.9	18
83	Detection of clinically significant prostate cancer with PI-RADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 713-723.	1.5	16
84	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 438-445.	3.9	22
85	Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy. <i>Urology</i> , 2019, 129, 165-171.	1.0	41
86	Assessment of ⁶⁸ Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856.	7.1	493
87	Longitudinal Comparison of Patient-Level Outcomes and Costs Across Prostate Cancer Treatments With Urinary Problems. <i>American Journal of Men's Health</i> , 2019, 13, 155798831983532.	1.6	2
88	Guidelines should be assessed based on the underlying evidence. <i>Cmaj</i> , 2019, 191, E871-E871.	2.0	0
89	Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1917-1925.	2.5	20
90	Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plans in Patients With Prostate Cancer. <i>Urology</i> , 2019, 125, 154-162.	1.0	20

#	ARTICLE	IF	CITATIONS
91	Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 910-916.	5.0	35
92	Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer. <i>European Urology</i> , 2019, 75, 950-958.	1.9	45
93	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2019, 111, 301-310.	6.3	142
94	Genomic Prostate Score, PI-RADSâ„¢ version 2 and Progression in Men with Prostate Cancer on Active Surveillance. <i>Journal of Urology</i> , 2019, 201, 300-307.	0.4	36
95	Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 90-95.	0.4	16
96	Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance. <i>Journal of Urology</i> , 2019, 202, 506-510.	0.4	22
97	Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 696-701.	0.4	16
98	A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance. <i>Journal of Urology</i> , 2019, 202, 702-709.	0.4	35
99	Trends in Complementary and Alternative Medicine Use among Patients with Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 689-695.	0.4	10
100	SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 952-958.	0.4	8
101	A Mobile Health Intervention for Prostate Biopsy Patients Reduces Appointment Cancellations: Cohort Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e14094.	4.3	7
102	Editorial Comment. <i>Journal of Urology</i> , 2019, 201, 298-299.	0.4	0
103	Reply by Authors. <i>Journal of Urology</i> , 2019, 202, 958-958.	0.4	0
104	Germline testing in those at risk of prostate cancer. <i>Canadian Journal of Urology</i> , 2019, 26, 31-33.	0.0	4
105	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. <i>European Urology</i> , 2018, 74, 211-217.	1.9	30
106	Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 215-223.	1.9	45
107	Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy. <i>Journal of Urology</i> , 2018, 199, 719-725.	0.4	4
108	Impact of Lesion Visibility on Transrectal Ultrasound on the Prediction of Clinically Significant Prostate Cancer (Gleason Score 3 + 4 or Greater) with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Biopsy. <i>Journal of Urology</i> , 2018, 199, 699-705.	0.4	16

#	ARTICLE	IF	CITATIONS
109	Cycling, and Male Sexual and Urinary Function: Results from a Large, Multinational, Cross-Sectional Study. <i>Journal of Urology</i> , 2018, 199, 798-804.	0.4	33
110	Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSUREâ„„,ç). <i>Prostate</i> , 2018, 78, 32-39.	2.3	22
111	Scatter Artifact with Ga-68-PSMA-11 PET: Severity Reduced With Furosemide Diuresis and Improved Scatter Correction. <i>Molecular Imaging</i> , 2018, 17, 153601211881174.	1.4	6
112	Diagnostic Accuracy of ⁶⁸ Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. <i>Radiology</i> , 2018, 289, 730-737.	7.3	114
113	A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen ≥ 10 ng/ml at Initial Biopsy. <i>European Urology</i> , 2018, 74, 731-738.	1.9	186
114	Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. <i>European Urology</i> , 2018, 74, 668-675.	1.9	34
115	Effect of Oscillation on Perineal Pressure in Cyclists: Implications for Micro-Trauma. <i>Sexual Medicine</i> , 2018, 6, 239-247.	1.6	11
116	USPTF Prostate Cancer Screening Recommendationsâ€”A Step in the Right Direction. <i>JAMA Surgery</i> , 2018, 153, 701.	4.3	3
117	Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. <i>Oncotarget</i> , 2018, 9, 6550-6561.	1.8	16
118	Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11257.	1.0	9
119	Quantified Clinical Risk Change as an End Point During Prostate Cancer Active Surveillance. <i>European Urology</i> , 2017, 72, 329-332.	1.9	8
120	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendationsâ€”A Report of a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 648-655.	1.9	190
121	Risk Stratification of Newly Diagnosed Prostate Cancer with Genomic Platforms. <i>Urology Practice</i> , 2017, 4, 322-328.	0.5	0
122	Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting. <i>Prostate International</i> , 2017, 5, 95-103.	2.3	7
123	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.	7.1	219
124	Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy. <i>Prostate</i> , 2017, 77, 425-434.	2.3	4
125	Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments. <i>Journal of Urology</i> , 2017, 198, 671-677.	0.4	16
126	Semantics in active surveillance for men with localized prostate cancer â€” results of a modified Delphi consensus procedure. <i>Nature Reviews Urology</i> , 2017, 14, 312-322.	3.8	65

#	ARTICLE	IF	CITATIONS
127	Low-risk Prostate Cancer: Identification, Management, and Outcomes. <i>European Urology</i> , 2017, 72, 238-249.	1.9	55
128	Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. <i>European Urology</i> , 2017, 71, 750-759.	1.9	40
129	Characterization and stratification of prostate lesions based on comprehensive multiparametric MRI using detailed whole-mount histopathology as a reference standard. <i>NMR in Biomedicine</i> , 2017, 30, e3796.	2.8	19
130	Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers. <i>Prostate</i> , 2017, 77, 1573-1582.	2.3	8
131	Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 663.e9-663.e14.	1.6	10
132	The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. <i>Cancer</i> , 2017, 123, 4574-4582.	4.1	36
133	What is the best way not to treat prostate cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 42-50.	1.6	13
134	Validity of the Cancer of the Prostate Risk Assessment Score Derived From Targeted Biopsy: Modeling Evidence From Ultrasound Lesion-Directed Biopsy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 93-99.	1.9	1
135	¹⁸ F Fluorocholine Dynamic Time-of-Flight PET/MR Imaging in Patients with Newly Diagnosed Intermediate- to High-Risk Prostate Cancer: Initial Clinical-Pathologic Comparisons. <i>Radiology</i> , 2017, 282, 429-436.	7.3	15
136	Magnetic Resonance Imaging–Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance. <i>European Urology</i> , 2017, 72, 275-281.	1.9	88
137	A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2017, 197, 369-375.	0.4	19
138	Impact of the integration of proton magnetic resonance imaging spectroscopy to PI-RADS 2 for prediction of high grade and high stage prostate cancer. <i>Radiologia Brasileira</i> , 2017, 50, 299-307.	0.7	11
139	Optimal MRI sequences for ⁶⁸ Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. <i>EJNMMI Research</i> , 2017, 7, 77.	2.5	33
140	Luminal and basal subtyping of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3-3.	1.6	2
141	Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). <i>PLoS ONE</i> , 2017, 12, e0185535.	2.5	22
142	The Fitbit One Physical Activity Tracker in Men With Prostate Cancer: Validation Study. <i>JMIR Cancer</i> , 2017, 3, e5.	2.4	35
143	The use of five-alpha reductase inhibitors and their association with reclassification and pathologic outcomes in the Canary Prostate Active Surveillance Study (PASS).. <i>Journal of Clinical Oncology</i> , 2017, 35, 22-22.	1.6	0
144	Luminal and basal subtyping of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 2017, 3-3.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy.. Journal of Clinical Oncology, 2017, 35, 110-110.	1.6	0
146	Validation of GEMCaP as a DNA based biomarker to predict disease recurrence in patients undergoing prostatectomy for prostate cancer.. Journal of Clinical Oncology, 2017, 35, 58-58.	1.6	0
147	Milk and other dairy foods in relation to prostate cancer progression: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CAPSURE).. Journal of Clinical Oncology, 2017, 35, 168-168.	1.6	1
148	Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Prostate, 2016, 76, 1409-1419.	2.3	19
149	Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal of Urology, 2016, 196, 1408-1414.	0.4	43
150	A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncology, 2016, 2, 882.	7.1	458
151	Serial Anatomical Prostate Ultrasound during Prostate Cancer Active Surveillance. Journal of Urology, 2016, 196, 727-733.	0.4	4
152	Immediate androgen deprivation: for all or for some?. Lancet Oncology, The, 2016, 17, 683-684.	10.7	3
153	An Approach Using PSA Levels of 1.5â€‰ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology, 2016, 96, 116-120.	1.0	11
154	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncology, The, 2016, 17, 1612-1620.	10.7	182
155	Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate, 2016, 76, 339-348.	2.3	32
156	PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. European Urology Focus, 2016, 2, 180-188.	3.1	60
157	Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. Journal of Molecular Diagnostics, 2016, 18, 395-406.	2.8	46
158	Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nature Reviews Urology, 2016, 13, 151-167.	3.8	139
159	New Genetic Markers for Prostate Cancer. Urologic Clinics of North America, 2016, 43, 7-15.	1.8	12
160	MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. PLoS ONE, 2016, 11, e0165236.	2.5	19
161	Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?. BJU International, 2015, 116, 713-720.	2.5	13
162	Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. PLoS ONE, 2015, 10, e0132343.	2.5	28

#	ARTICLE	IF	CITATIONS
163	Patterns of Local Failure following Radiation Therapy for Prostate Cancer. <i>Journal of Urology</i> , 2015, 194, 977-982.	0.4	39
164	A multicenter study shows <i>PTEN</i> deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. <i>Prostate</i> , 2015, 75, 1206-1215.	2.3	55
165	Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors. <i>Science Signaling</i> , 2015, 8, ra116.	3.6	37
166	Active Surveillance for Low-risk Prostate Cancer: Developments to Date. <i>European Urology</i> , 2015, 67, 646-648.	1.9	25
167	Extended Followup and Risk Factors for Disease Reclassification in a Large Active Surveillance Cohort for Localized Prostate Cancer. <i>Journal of Urology</i> , 2015, 193, 807-811.	0.4	148
168	Current Use of Imaging after Primary Treatment of Prostate Cancer. <i>Journal of Urology</i> , 2015, 194, 98-104.	0.4	4
169	What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer?. <i>Journal of Urology</i> , 2015, 194, 615-616.	0.4	1
170	Immediate Versus Delayed Radical Prostatectomy: Updated Outcomes Following Active Surveillance of Prostate Cancer. <i>European Urology</i> , 2015, 68, 458-463.	1.9	49
171	Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 80.	7.4	543
172	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary Early Detection Research Network Active Surveillance Biopsy Risk Calculator. <i>European Urology</i> , 2015, 68, 1083-1088.	1.9	48
173	Bicycle Trauma Injuries and Hospital Admissions in the United States, 1998-2013. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 947.	7.4	46
174	Treatment Trends for Prostate Cancer—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1977.	7.4	2
175	Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes. <i>PLoS ONE</i> , 2014, 9, e89754.	2.5	17
176	miR-19, miR-345, miR-519c-5p Serum Levels Predict Adverse Pathology in Prostate Cancer Patients Eligible for Active Surveillance. <i>PLoS ONE</i> , 2014, 9, e98597.	2.5	41
177	Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. <i>BJU International</i> , 2014, 114, E18-E24.	2.5	43
178	Serial Prostate Biopsy and Risk of Lower Urinary Tract Symptoms: Results From a Large, Single-institution Active Surveillance Cohort. <i>Urology</i> , 2014, 83, 33-39.	1.0	13
179	Autologous retro-pubic urethral sling: a novel, quick, intra-operative technique to improve continence after robotic-assisted radical prostatectomy. <i>Journal of Robotic Surgery</i> , 2014, 8, 99-104.	1.8	7
180	Early Salvage Radiotherapy Following Radical Prostatectomy. <i>European Urology</i> , 2014, 65, 1034-1043.	1.9	171

#	ARTICLE	IF	CITATIONS
181	Overdiagnosis and Overtreatment of Prostate Cancer. <i>European Urology</i> , 2014, 65, 1046-1055.	1.9	709
182	Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's Letter to the Editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. <i>Eur Urol</i> 2014;66:550-60. <i>European Urology</i> , 2014, 66, e117-e118.	1.9	8
183	Impact of Folate Intake on Prostate Cancer Recurrence Following Definitive Therapy: Data from CaPSURE. <i>J. Journal of Urology</i> , 2014, 191, 971-976.	0.4	17
184	Evolution and Immediate Future of US Screening Guidelines. <i>Urologic Clinics of North America</i> , 2014, 41, 229-235.	1.8	3
185	Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: Quantitative analysis of imaging contour compared to whole-mount histopathology. <i>Radiotherapy and Oncology</i> , 2014, 110, 303-308.	0.6	39
186	The Ongoing Need for Improved Risk Stratification and Monitoring for Those on Active Surveillance for Early Stage Prostate Cancer. <i>European Urology</i> , 2014, 65, 1032-1033.	1.9	7
187	Age and Baseline Quality of Life at Radical Prostatectomy: Who Has the Most to Lose?. <i>Journal of Urology</i> , 2014, 192, 396-401.	0.4	24
188	A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. <i>European Urology</i> , 2014, 66, 550-560.	1.9	553
189	A Commentary on PSA Velocity and Doubling Time for Clinical Decisions in Prostate Cancer. <i>Urology</i> , 2014, 83, 592-598.	1.0	43
190	Predictors of Pathologic Progression on Biopsy Among Men on Active Surveillance for Localized Prostate Cancer: The Value of the Pattern of Surveillance Biopsies. <i>European Urology</i> , 2014, 66, 337-342.	1.9	56
191	Impact of Androgen Deprivation Therapy on Mental and Emotional Well-Being in Men with Prostate Cancer: Analysis from the CaPSURE Registry. <i>Journal of Urology</i> , 2014, 191, 964-970.	0.4	36
192	Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy. <i>European Urology</i> , 2014, 65, 1171-1177.	1.9	110
193	Point/Counterpoint: Early Detection of Prostate Cancer: Do the Benefits Outweigh the Consequences?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 768-771.	4.9	8
194	Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. <i>Lancet Oncology</i> , The, 2013, 14, 1112-1120.	10.7	321
195	The argument for palliative care in prostate cancer. <i>Translational Andrology and Urology</i> , 2013, 2, 278-80.	1.4	6
196	Physical Activity after Diagnosis and Risk of Prostate Cancer Progression: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. <i>Cancer Research</i> , 2011, 71, 3889-3895.	0.9	241
197	Reply to comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. <i>Cancer</i> , 2011, 117, 3532-3533.	4.1	1
198	IL4 Androgen Deprivation Therapy for Prostate Cancer : A US Perspective. <i>Japanese Journal of Urology</i> , 2010, 101, 53.	0.1	0

#	ARTICLE	IF	CITATIONS
199	THE IMPACT OF PATIENT ADVOCACY: THE UNIVERSITY OF CALIFORNIA-SAN FRANCISCO EXPERIENCE. Journal of Urology, 2004, 172, S58-61; discussion S61-2.	0.4	5
200	Predictors of Secondary Cancer Treatment in Patients Receiving Local Therapy for Prostate Cancer: Data From Cancer of the Prostate Strategic Urologic Research Endeavor. Journal of Urology, 2002, 168, 530-535.	0.4	88
201	Origin of Urothelial Carcinoma After Renal Transplant Determined by Fluorescence In Situ Hybridization. Journal of Urology, 2002, 167, 2521-2522.	0.4	6
202	Contemporary Trends in Imaging Test Utilization for Prostate Cancer Staging: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Journal of Urology, 2002, 168, 491-495.	0.4	69
203	IS ANASTOMOTIC BIOPSY NECESSARY BEFORE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY?. Journal of Urology, 2001, 166, 111-115.	0.4	73
204	UNDER STAGING AND UNDER GRADING IN A CONTEMPORARY SERIES OF PATIENTS UNDERGOING RADICAL PROSTATECTOMY: RESULTS FROM THE CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR DATABASE. Journal of Urology, 2001, 165, 851-856.	0.4	154
205	Is it necessary to do staging pelvic lymph node dissection for T1c prostate cancer?. Current Urology Reports, 2001, 2, 237-241.	2.2	4
206	Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magnetic Resonance in Medicine, 2001, 46, 49-57.	3.0	120
207	Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. Cancer, 1998, 83, 538-546.	4.1	53
208	Continenence mechanism of the ileal neobladder in women: a urodynamics study. World Journal of Urology, 1998, 16, 400-404.	2.2	32
209	LOCALLY RECURRENT PROSTATE TUMORS FOLLOWING EITHER RADIATION THERAPY OR RADICAL PROSTATECTOMY HAVE CHANGES IN KI-67 LABELING INDEX, P53 AND BCL-2 IMMUNOREACTIVITY. Journal of Urology, 1998, 159, 1437-1443.	0.4	81
210	Surgery of the Prostate Resnick M.I. and Thompson I.M.: Surgery of the Prostate. New York: Churchill Livingstone, Inc. 1998. , 387 pages.. Journal of Urology, 1998, 159, 2268-2269.	0.4	0
211	USE OF IMAGING TESTS FOR STAGING NEWLY DIAGNOSED PROSTATE CANCER: TRENDS FROM THE CAPSURE DATABASE. Journal of Urology, 1998, 160, 2102-2106.	0.4	56
212	Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes and Cancer, 1997, 19, 84-89.	2.8	49
213	A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. , 1996, 78, 1775-1780.		23
214	Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer. International Journal of Cancer, 1995, 64, 99-103.	5.1	61
215	Editorial: Prostate Cancer – “Many Treatments But Not Enough Answers. Journal of Urology, 1995, 154, 454-455.	0.4	3
216	Nephrectomy for metastatic renal cell carcinoma: A component of systemic treatment regimens. Journal of Surgical Oncology, 1994, 55, 7-13.	1.7	36

#	ARTICLE	IF	CITATIONS
217	Editorial: Laparoscopic Urological Surgery: Differentiating What Should Be Done from What Can Be Done. Journal of Urology, 1994, 151, 1603-1604.	0.4	6
218	The Value of Prostate Specific Antigen and Transrectal Ultrasound Guided Biopsy in Detecting Prostatic Fossa Recurrences Following Radical Prostatectomy. Journal of Urology, 1993, 149, 1024-1028.	0.4	109
219	Pyoderma Gangrenosum Presenting as Fournier's Gangrene. Journal of Urology, 1990, 144, 984-986.	0.4	36
220	Ureteral Obstruction Caused by Vasculitis. Journal of Urology, 1989, 141, 933-935.	0.4	23
221	Renal Trauma: Re-Evaluation of the Indications for Radiographic Assessment. Journal of Urology, 1985, 133, 183-186.	0.4	95
222	Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. Journal of Urology, 0, , .	0.4	1